Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Strand Therapeutics has raised seed funding to develop an mRNA engineering platform based on MIT research as it looks to assemble a pipeline of oncological drug candidates.

Bio-Techne has bought University of Minnesota-founded genome editing platform operator B-Mogen Biotechnologies to solidify a business relationship that dates to 2016.

Deerfield Management and Columbia University have launched a $130m commercialisation fund, Hudson Heights Innovation, to support the university's early-stage biomedical research.

Boehringer Ingelheim Venture Fund co-led the oncology drug developer's series A round with Delos Capital and Xeraya Capital.

OncoMyx Therapeutics was co-founded by ASU's Grant McFadden and will use the series A funding to advance the development of its lead asset aimed at several indications of cancer.

Zuellig Pharma has paid an undisclosed amount for portfolio company Klinify after investing in the healthcare data software provider two years ago.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UT Health's pulmonary drug treatment spinout Lung Therapeutics has raised a $36m series C, adding to at least $55m in previous funding from backers including UT Horizon Fund.

University of Colorado Hospital-affiliated UC Health and University of Virginia LVG Venture Fund both featured in a series A round for healthcare analytics platform creator RxRevu.